Droxidopa Norepinephrine Precursor for Mood Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mood disorders, sleep disorders, and attention deficit disorders often have limited effectiveness and are associated with undesirable side effects, highlighting a need for more pharmaceutical compositions that can effectively address these conditions.
Innovation Solution
The use of droxidopa alone or in combination with other pharmaceutically active compounds, such as DOPA decarboxylase inhibitors, catechol-O-methyltransferase inhibitors, and selective serotonin reuptake inhibitors, to increase norepinephrine levels in the central nervous system, thereby treating mood disorders, sleep disorders, and attention deficit disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (tricyclics, SSRIs, MAO inhibitors) are used to treat mood disorders, then depression symptoms can be managed, but undesirable side effects occur and effectiveness varies among patients
Solution Approach 1:
The patent changes the chemical parameter by using droxidopa (a norepinephrine precursor) instead of traditional antidepressants, fundamentally altering the mechanism of action from receptor modulation to direct neurotransmitter precursor supplementation, thereby achieving different side effect profiles and effectiveness patterns
Solution Approach 2:
The patent introduces droxidopa as an intermediary substance that converts to norepinephrine in the body, serving as a mediator that indirectly increases norepinephrine levels without directly administering norepinephrine itself, allowing for controlled conversion and reduced side effects
2Quantity of substance
If droxidopa is used to treat mood disorders, sleep disorders, or attention deficit disorders, then norepinephrine levels in the central nervous system increase, but the blood-brain barrier limits direct permeability
Solution Approach 1:
The patent uses droxidopa as an intermediary that can cross the blood-brain barrier more effectively than norepinephrine itself, then converts to norepinephrine within the CNS, bypassing the permeability barrier issue while achieving the desired neurotransmitter increase
Solution Approach 2:
The patent replaces the mechanical approach of directly administering norepinephrine (which cannot cross the blood-brain barrier) with a chemical precursor approach using droxidopa, substituting the delivery mechanism to overcome the biological barrier
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of droxidopa and its combinations effectively reduces the severity and frequency of symptoms in mood disorders, narcolepsy, insomnia, and attention deficit disorders, offering a potential alternative to existing treatments with fewer side effects.
Implementation Method 1
it is directly converted to 1-norepinephrine by the action of the aromatic L-amino acid decarboxylase which is widely distributed in a living body
Data Source
AI summary
The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD).